Second Gene Therapy Research Paper
William Brockmon
PLS 200-005
10/18/18
The Associated Press. “US Regulators Approve 2nd Gene Therapy for Blood Cancer.” New York Times. October 18th. The Food and Drug Administration(FDA) approved a second gene therapy for a for a type of blood cancer and allowed the sales of the treatment from Kite Pharma. The therapy uses the same technology as the first gene therapy that the FDA approved in the U.S. in August. The treatment, called Yescaarta, is estimated to cost $373,000 per patient. The technology, CAR-T, doesn’t fix the diseases-causing genes but attempts to turbocharge T cells, immune system soldiers that cancer can often evade. These T-cells are reprogrammed to kill cancers cells, the cell will then multiple itself into hundreds of millions of copies, allowing it to fight the disease for years. The therapy is for three types of cancer, aggressive, or fast-growing and large B-cell lymphoma. Yescarta was approved for patients who have been resistant to at least two cancer drugs. Three people have died after getting this treatment, due to its serious side effects. Due to …show more content…
The agency defines the role or function that it preforms not the person in charge of the agency. Once the role of the agency is defined someone can be hired or trained to fill that role, and if that person leaves the role another can replace them with little or no disruption. He also goes on to explain, that the administrative institutions stay relatively consistent in their government function and activity regardless of the official in charge. The rules, procedures, and processes of the administrative institutions define the actions of the official. This adherence to these rules is what creates the desired consistency and turns the official into a mindless functionary who is unable to deal with anything outside of the bounds of the rules the official is supposed to
PLS 200-005
10/18/18
The Associated Press. “US Regulators Approve 2nd Gene Therapy for Blood Cancer.” New York Times. October 18th. The Food and Drug Administration(FDA) approved a second gene therapy for a for a type of blood cancer and allowed the sales of the treatment from Kite Pharma. The therapy uses the same technology as the first gene therapy that the FDA approved in the U.S. in August. The treatment, called Yescaarta, is estimated to cost $373,000 per patient. The technology, CAR-T, doesn’t fix the diseases-causing genes but attempts to turbocharge T cells, immune system soldiers that cancer can often evade. These T-cells are reprogrammed to kill cancers cells, the cell will then multiple itself into hundreds of millions of copies, allowing it to fight the disease for years. The therapy is for three types of cancer, aggressive, or fast-growing and large B-cell lymphoma. Yescarta was approved for patients who have been resistant to at least two cancer drugs. Three people have died after getting this treatment, due to its serious side effects. Due to …show more content…
The agency defines the role or function that it preforms not the person in charge of the agency. Once the role of the agency is defined someone can be hired or trained to fill that role, and if that person leaves the role another can replace them with little or no disruption. He also goes on to explain, that the administrative institutions stay relatively consistent in their government function and activity regardless of the official in charge. The rules, procedures, and processes of the administrative institutions define the actions of the official. This adherence to these rules is what creates the desired consistency and turns the official into a mindless functionary who is unable to deal with anything outside of the bounds of the rules the official is supposed to